• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

HOXB13基因中的同义多态性作为前列腺癌的保护因素

Synonymous Polymorphisms in HOXB13 as a Protective Factor for Prostate Cancer.

作者信息

Albitar Ferras, Diep Kevin, Ma Wanlong, Albitar Maher

机构信息

NeoGenomics Laboratories, 5 Jenner Suite 100, Irvine, CA USA 92618.

出版信息

J Cancer. 2015 Feb 27;6(5):409-11. doi: 10.7150/jca.11413. eCollection 2015.

DOI:10.7150/jca.11413
PMID:25874003
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4392048/
Abstract

BACKGROUND

Genomic association and linkage studies, as well as epidemiological data have implicated both the HOXB13 gene and single nucleotide polymorphisms (SNPs) in the development of prostate cancer (PCa). The recent association between the G84E polymorphism in the HOXB13 gene and PCa has been shown to result in a more aggressive cancer with an earlier onset of the disease. We examined the frequency of this mutation and other recurrent HOXB13 SNPs in patients with PCa and those with benign prostatic hyperplasia (BPH) or no cancer.

METHODS

Reverse transcriptase-polymerase chain reaction (RT-PCR) was performed on exons 1 and 2 of HOXB13 gene, followed by bidirectional Sanger Sequencing on peripheral blood from 232 PCa (age 46-92) and 110 BPH (age 45-84) patients. Statistical analysis was used to correlate between recurrent SNPs and PCa.

RESULTS

The G84E mutation was found at a low frequency in randomly selected PCa and BPH (both 0.9%). Two recurrent, synonymous SNPs, rs8556 and rs900627, were also detected. rs8556 was detected in 48 PCa (20.7%) and 26 BPH (23.6%) subjects; rs9900627was detected in 27 PCa (11.6%) and 19 BPH (17.3%) subjects. Having both rs8556 and rs9900627 or being homozygous for either one was associated with being 2.9 times less likely to develop PCa (p=0.05).

CONCLUSIONS

Although a larger study in order to confirm our findings, our data suggests a significant negative correlation between two SNPs, rs8556 and rs9900627, and the presence of PCa.

摘要

背景

基因组关联和连锁研究以及流行病学数据表明,HOXB13基因和单核苷酸多态性(SNP)均与前列腺癌(PCa)的发生有关。最近研究显示,HOXB13基因中的G84E多态性与PCa之间的关联会导致癌症更具侵袭性且发病更早。我们检测了PCa患者以及良性前列腺增生(BPH)患者或无癌患者中该突变及其他常见HOXB13 SNP的频率。

方法

对HOXB13基因的第1和第2外显子进行逆转录聚合酶链反应(RT-PCR),随后对232例PCa患者(年龄46 - 92岁)和110例BPH患者(年龄45 - 84岁)的外周血进行双向桑格测序。采用统计分析来关联常见SNP与PCa。

结果

在随机选择的PCa和BPH患者中均低频率发现G84E突变(均为0.9%)。还检测到两个常见的同义SNP,即rs8556和rs900627。在48例PCa患者(20.7%)和26例BPH患者(23.6%)中检测到rs8556;在27例PCa患者(11.6%)和19例BPH患者(17.3%)中检测到rs9900627。同时具有rs8556和rs9900627或其中任何一个为纯合子与患PCa的可能性降低2.9倍相关(p = 0.05)。

结论

尽管需要更大规模的研究来证实我们的发现,但我们的数据表明rs8556和rs9900627这两个SNP与PCa的存在之间存在显著的负相关。

相似文献

1
Synonymous Polymorphisms in HOXB13 as a Protective Factor for Prostate Cancer.HOXB13基因中的同义多态性作为前列腺癌的保护因素
J Cancer. 2015 Feb 27;6(5):409-11. doi: 10.7150/jca.11413. eCollection 2015.
2
Association of homeobox B13 (HOXB13) gene variants with prostate cancer risk in an Iranian population.伊朗人群中同源框B13(HOXB13)基因变异与前列腺癌风险的关联。
Med J Islam Repub Iran. 2018 Oct 7;32:97. doi: 10.14196/mjiri.32.97. eCollection 2018.
3
Evaluation of homeobox protein B13 (HOXB13) gene G84E mutation in patients with prostate cancer.评估前列腺癌患者中同源盒蛋白 B13(HOXB13)基因 G84E 突变。
World J Urol. 2024 Aug 8;42(1):476. doi: 10.1007/s00345-024-05186-9.
4
Prevalence of the HOXB13 G84E mutation in Danish men undergoing radical prostatectomy and its correlations with prostate cancer risk and aggressiveness.丹麦接受根治性前列腺切除术男性中HOXB13 G84E突变的患病率及其与前列腺癌风险和侵袭性的相关性。
BJU Int. 2016 Oct;118(4):646-53. doi: 10.1111/bju.13416. Epub 2016 Feb 12.
5
G84E mutation in HOXB13 is firmly associated with prostate cancer risk: a meta-analysis.HOXB13基因中的G84E突变与前列腺癌风险密切相关:一项荟萃分析。
Tumour Biol. 2014 Feb;35(2):1177-82. doi: 10.1007/s13277-013-1157-5. Epub 2013 Sep 13.
6
Homeobox B13 G84E Mutation and Prostate Cancer Risk.同源盒 B13 G84E 突变与前列腺癌风险。
Eur Urol. 2019 May;75(5):834-845. doi: 10.1016/j.eururo.2018.11.015. Epub 2018 Dec 8.
7
HOXB13 interaction with MEIS1 modifies proliferation and gene expression in prostate cancer.HOXB13 与 MEIS1 的相互作用改变了前列腺癌的增殖和基因表达。
Prostate. 2019 Mar;79(4):414-424. doi: 10.1002/pros.23747. Epub 2018 Dec 17.
8
Symptomatic Benign Prostatic Hyperplasia with Suppressed Epigenetic Regulator HOXB13 Shows a Lower Incidence of Prostate Cancer Development.伴有表观遗传调节因子HOXB13抑制的症状性良性前列腺增生显示前列腺癌发生的发生率较低。
Cancers (Basel). 2024 Jan 2;16(1):213. doi: 10.3390/cancers16010213.
9
A population-based assessment of germline HOXB13 G84E mutation and prostate cancer risk.基于人群的种系 HOXB13 G84E 突变与前列腺癌风险评估。
Eur Urol. 2014 Jan;65(1):169-76. doi: 10.1016/j.eururo.2012.07.027. Epub 2012 Jul 20.
10
HOXB13 G84E mutation in Finland: population-based analysis of prostate, breast, and colorectal cancer risk.芬兰 HOXB13 G84E 突变:前列腺癌、乳腺癌和结直肠癌风险的基于人群的分析。
Cancer Epidemiol Biomarkers Prev. 2013 Mar;22(3):452-60. doi: 10.1158/1055-9965.EPI-12-1000-T. Epub 2013 Jan 4.

引用本文的文献

1
HOXB13 in cancer development: molecular mechanisms and clinical implications.HOXB13在癌症发展中的作用:分子机制与临床意义
Front Med. 2025 Mar 11. doi: 10.1007/s11684-024-1119-x.
2
Homeobox B13 G84E Mutation and Prostate Cancer Risk.同源盒 B13 G84E 突变与前列腺癌风险。
Eur Urol. 2019 May;75(5):834-845. doi: 10.1016/j.eururo.2018.11.015. Epub 2018 Dec 8.
3
Synergistic Interaction of and Predisposes to Aggressive Prostate Cancer.和协同作用导致侵袭性前列腺癌。
Clin Cancer Res. 2018 Dec 15;24(24):6265-6276. doi: 10.1158/1078-0432.CCR-18-0444. Epub 2018 Sep 4.
4
Identification of a synonymous variant in TRIM59 gene for gastric cancer risk in a Chinese population.在中国人群中鉴定TRIM59基因的一个同义变体与胃癌风险的关系。
Oncotarget. 2017 Feb 14;8(7):11507-11516. doi: 10.18632/oncotarget.14075.
5
Association between germline homeobox B13 (HOXB13) G84E allele and prostate cancer susceptibility: a meta-analysis and trial sequential analysis.种系同源盒B13(HOXB13)G84E等位基因与前列腺癌易感性之间的关联:一项荟萃分析和试验序贯分析
Oncotarget. 2016 Oct 11;7(41):67101-67110. doi: 10.18632/oncotarget.11937.
6
Germline HOXB13 p.Gly84Glu mutation and cancer susceptibility: a pooled analysis of 25 epidemiological studies with 145,257 participates.种系HOXB13基因p.Gly84Glu突变与癌症易感性:对25项流行病学研究中145257名参与者的汇总分析
Oncotarget. 2015 Dec 8;6(39):42312-21. doi: 10.18632/oncotarget.5994.

本文引用的文献

1
The role of single nucleotide polymorphisms in predicting prostate cancer risk and therapeutic decision making.单核苷酸多态性在预测前列腺癌风险及治疗决策中的作用。
Biomed Res Int. 2014;2014:627510. doi: 10.1155/2014/627510. Epub 2014 Feb 19.
2
G84E mutation in HOXB13 is firmly associated with prostate cancer risk: a meta-analysis.HOXB13基因中的G84E突变与前列腺癌风险密切相关:一项荟萃分析。
Tumour Biol. 2014 Feb;35(2):1177-82. doi: 10.1007/s13277-013-1157-5. Epub 2013 Sep 13.
3
Genetics and genomics of prostate cancer.前列腺癌的遗传学和基因组学。
Asian J Androl. 2013 May;15(3):309-13. doi: 10.1038/aja.2013.29. Epub 2013 Apr 8.
4
Cancer statistics, 2013.癌症统计数据,2013 年。
CA Cancer J Clin. 2013 Jan;63(1):11-30. doi: 10.3322/caac.21166. Epub 2013 Jan 17.
5
HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG).HOXB13 是前列腺癌的易感基因:来自前列腺癌遗传国际合作研究组(ICPCG)的研究结果。
Hum Genet. 2013 Jan;132(1):5-14. doi: 10.1007/s00439-012-1229-4. Epub 2012 Oct 12.
6
Germline mutations in HOXB13 and prostate-cancer risk.HOXB13 种系突变与前列腺癌风险。
N Engl J Med. 2012 Jan 12;366(2):141-9. doi: 10.1056/NEJMoa1110000.
7
Selection for translation efficiency on synonymous polymorphisms in recent human evolution.近期人类进化中同义多态性的翻译效率选择。
Genome Biol Evol. 2011;3:749-61. doi: 10.1093/gbe/evr076. Epub 2011 Jul 29.
8
Genome-wide association study identifies new prostate cancer susceptibility loci.全基因组关联研究鉴定出新的前列腺癌易感性位点。
Hum Mol Genet. 2011 Oct 1;20(19):3867-75. doi: 10.1093/hmg/ddr295. Epub 2011 Jul 8.
9
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008.2008 年全球癌症负担估计值:GLOBOCAN 2008。
Int J Cancer. 2010 Dec 15;127(12):2893-917. doi: 10.1002/ijc.25516.
10
Global cancer statistics.全球癌症统计数据。
CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90. doi: 10.3322/caac.20107. Epub 2011 Feb 4.